<DOC>
	<DOCNO>NCT02442908</DOCNO>
	<brief_summary>SF-K002 pilot study patient moderate severe COPD suffer involuntary weight loss . The study 12 week , double-blinded , placebo control main objective study safety tolerability Nutrifriend Cachexia .</brief_summary>
	<brief_title>Pilot Study Safety Tolerability Nutrifriend Cachexia COPD Cachexia</brief_title>
	<detailed_description>This study 12-week , randomise , parallel group , placebo control , multi-centre study . The primary objective evaluate safety tolerability Nutrifriend Cachexia patient COPD . The secondary objective study evaluate effect body composition , muscle function , daily activity , inflammation , lung function , compliance , appetite Quality Life .</detailed_description>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Cachexia</mesh_term>
	<criteria>Age &gt; 50 year Moderate severe COPD patient force expiratory volume ( FEV1 ) 3060 % Involuntary weight loss &lt; 10 % 18 kg/m2 ≤ BMI ≤ 32 kg/m2 Exacerbation COPD within 3 month prior screen Treatment oral corticosteroid ( &gt; 5 mg/day ) within 3 month prior screen Treatment anabolic steroid within 3 month prior screen Current oxygen treatment home ventilation therapy Change smoking habit previous 6 month Major change COPD maintenance treatment within 3 month prior screen Other cachectic disorder cancer , renal hepatic disorder</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>